Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 358

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 358
---
 oversight. We believe that timely and precise genomic insights play a critical role in revolutionizing individual health management. In today’s landscape, reliable genetic data remains elusive for many, leaving them vulnerable to undetected disease -pronegenetic variants. According to the American Association for the Advancement of Science, one in five healthy adults may carry such variants, without knowing it. If left unchecked, these mutations could profoundly impact their health, affect family members, or alter their responses to treatments. Recognizing the importance of understanding one’s genetic makeup, we envision a future where genetic sequencing is integral to healthcare, beginning at birth and throughout the various stages of life. To achieve our vision, we have developed a suite of personalized medicine services that currently cover the following categories: • Wellness & Prevention: preventative health solutions that integrate genetic, microbiome and lifestyle data, enabling individuals to understand how their unique genes and habits impact their long -termhealth. These solutions also provide actionable prevention recommendations, and will be supported by nutrigenetic specialists who will help craft personalized preventive health strategies tailored to each individual’s specific needs; and • Diagnostics, Prognosis & Monitoring: precise clinical genetic services integrated with clinical data to enable accurate diagnostics and informed treatment decisions, covering the fields of oncology, prenatal care, rare diseases and human microbiome. Our portfolio aims to empower individuals to understand and make decisions based on their genetic results. We achieve this by possessing a unique scientific know -howthat allows us to sequence biological samples in -houseand a R&D division that continuously works to develop innovative genomic services, and potentially integrate the omni -modaldata with complex analytics to accelerate our innovation. To deliver our services, we process blood, tissue, microbiome and saliva samples from our own sales channels and partners. According to the public report titled “Predictive Genetic Testing and Consumer Genomics Market Research 2024 -2034”, published by Erevna Healthcare on Research and Markets, dated January23, 2025, a significant increase in interest in genetics among both consumers and healthcare professionals is expected, as the market adoption of genetic tests has experienced significant growth globally, driven by increased emphasis on early disease detection, personalized medicine, and genetics in addressing health conditions. An industry public report titled “Latin America Precision Medicine Market Size & Outlook”, published by Horizon Grand View Research during 2023 estimates that the Latin American genomics market will be valued at approximately $6.15 billion by 2030, growing at a compound annual growth rate (CAGR) of